AR008614A1 - UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMI - Google Patents
UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMIInfo
- Publication number
- AR008614A1 AR008614A1 ARP970102715A ARP970102715A AR008614A1 AR 008614 A1 AR008614 A1 AR 008614A1 AR P970102715 A ARP970102715 A AR P970102715A AR P970102715 A ARP970102715 A AR P970102715A AR 008614 A1 AR008614 A1 AR 008614A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- pirimidine
- manufacture
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- 102000001253 Protein Kinase Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 108060006633 protein kinase Proteins 0.000 title 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- -1 pyrimidine compound Chemical class 0.000 abstract 4
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Abstract
Un procedimiento para la fabricacion de una composicion farmacéutica que contiene un compuesto de pirimidina o una sal farmacéuticamente aceptable delmismo, que tiene actividad inhibitoria de la tirosina quinasa. El compuesto de pirimidina responde a la formula (I) donde A es una cadena cerrada de benceno oimidazol; B es una cadena cerrada de benceno, tetralina, indano o 2-oxindol; R es perfluoalquilo (C1-C4), fenilo fenil-alquilo (C1-C4), hidroxi-alquilo(C1-C4), alcoxi (C1-C4)-alquilo (C1-C4), aciloxi(C2-C4)-alquilo(C1-C4), halobenzoiloxi-alquilo(C1-C4), carboxi, carbamoílo, alcoxicarbonilo (C1-C4),ciano, alquilcarbonilo (C1-C4), carboxi-alquilo(C1-C4), carbamoil-alquilo (C1- C4), alcoxicarbonil(C1-C4)-alquilo(C1-C4), halo-alquilo(C1-C4), amino-alquilo(C1-C4), mono- o di-alquilamino (C1-C4)-alquilo (C1-C4), sulfo-alquilo (C1-C4) o sulfamido-alquilo (C1-C4); cada una de R1 y R2, las cuales pueden ser igualeso diferentes, es hidrogeno, alquilo C1-C4, alcoxi C1-C4, halogeno o -NR5R6, en la que cada una de R5 y R6, que pueden ser iguales o diferentes, es H o alquiloC1-C4; cada una de R3 y R4, pueden ser iguales o diferentes, es hidrogeno, alquilo C1-C4, Halogeno, hidroxi, alcoxi C1-C4, alcoxicarbonilo C1-C4,nitro,ciano o CF3. Compuestos de pirimidina, a composiciones Farmacéuticas que los comprenden y a un procedimiento para preparar un compuesto de pirimidina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9613021.6A GB9613021D0 (en) | 1996-06-21 | 1996-06-21 | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR008614A1 true AR008614A1 (es) | 2000-02-09 |
Family
ID=10795666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102715A AR008614A1 (es) | 1996-06-21 | 1997-06-20 | UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMI |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6057326A (es) |
| EP (1) | EP0853616B1 (es) |
| JP (1) | JPH11511761A (es) |
| KR (1) | KR19990043993A (es) |
| CN (1) | CN1198158A (es) |
| AR (1) | AR008614A1 (es) |
| AT (1) | ATE205836T1 (es) |
| AU (1) | AU3094197A (es) |
| BR (1) | BR9702328A (es) |
| CA (1) | CA2228492C (es) |
| DE (1) | DE69706823T2 (es) |
| EA (1) | EA199800215A1 (es) |
| ES (1) | ES2165061T3 (es) |
| GB (1) | GB9613021D0 (es) |
| HU (1) | HUP9902026A3 (es) |
| IL (1) | IL123124A0 (es) |
| NO (1) | NO980718L (es) |
| PL (1) | PL325122A1 (es) |
| WO (1) | WO1997049689A1 (es) |
| ZA (1) | ZA975380B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6347480B1 (en) * | 1997-07-07 | 2002-02-19 | Southpac Trust International, Inc. | Method for wrapping a floral grouping with a sheet of material constructed of paper and having printed and embossed patterns thereon |
| BR9707495A (pt) | 1996-02-13 | 1999-07-27 | Zeneca Ltd | Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente |
| AU719327B2 (en) | 1996-03-05 | 2000-05-04 | Astrazeneca Ab | 4-anilinoquinazoline derivatives |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6608060B1 (en) | 1996-12-18 | 2003-08-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| DE19653646A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| TR200500745T2 (tr) * | 1999-02-10 | 2005-05-23 | Astrazeneca Ab | Damar gelişimi inhibitörleri olarak kuinazolin türevleri. |
| AU1071301A (en) * | 1999-11-01 | 2001-05-14 | Eli Lilly And Company | Pharmaceutical compounds |
| PL203782B1 (pl) | 1999-11-05 | 2009-11-30 | Astrazeneca Ab | Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania |
| CA2403365A1 (en) | 2000-04-07 | 2001-10-18 | Astrazeneca Ab | Quinazoline compounds |
| WO2003009852A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| KR100468352B1 (ko) * | 2002-09-24 | 2005-01-27 | 한국과학기술연구원 | 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물 |
| SG145748A1 (en) * | 2003-08-15 | 2008-09-29 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
| JP4934432B2 (ja) * | 2004-02-19 | 2012-05-16 | レクサン ファーマシューティカルズ インコーポレイテッド | キナゾリン誘導体およびキナゾリン誘導体の治療への使用 |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| ATE421510T1 (de) * | 2005-03-28 | 2009-02-15 | Bristol Myers Squibb Co | Kompetitive atp-kinasehemmer |
| CN102264745B (zh) * | 2008-11-10 | 2015-07-22 | 财团法人卫生研究院 | 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物 |
| UA110113C2 (xx) * | 2010-07-29 | 2015-11-25 | Біциклічні азагетероциклічні карбоксаміди | |
| JP5961187B2 (ja) * | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン |
| WO2020206363A1 (en) * | 2019-04-03 | 2020-10-08 | Mitokinin,Inc. | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT198900008A (es) * | 1988-01-29 | 1990-07-17 | Derivados de quinolina, quinazolina y cinolina. | |
| ZA902280B (en) * | 1989-03-29 | 1990-12-28 | Merrell Dow Pharma | Selective adenosine receptor agents |
| JP2762430B2 (ja) * | 1991-01-18 | 1998-06-04 | 宇部興産株式会社 | アラルキルアミノピリミジン類の製法 |
| US5710158A (en) * | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| JPH06172321A (ja) * | 1992-10-08 | 1994-06-21 | Agro Kanesho Co Ltd | 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤 |
| GB9313638D0 (en) * | 1993-07-01 | 1993-08-18 | Erba Carlo Spa | Arylidene and heteroarylidene oxindole derivatives and process for their preparation |
| GB9326136D0 (en) * | 1993-12-22 | 1994-02-23 | Erba Carlo Spa | Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| GB9406137D0 (en) * | 1994-03-28 | 1994-05-18 | Erba Carlo Spa | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
| GB9412719D0 (en) * | 1994-06-24 | 1994-08-17 | Erba Carlo Spa | Substituted azaindolylidene compounds and process for their preparation |
| GB9423997D0 (en) * | 1994-11-28 | 1995-01-11 | Erba Carlo Spa | Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation |
-
1996
- 1996-06-21 GB GBGB9613021.6A patent/GB9613021D0/en active Pending
-
1997
- 1997-06-03 JP JP10502193A patent/JPH11511761A/ja not_active Ceased
- 1997-06-03 AT AT97925987T patent/ATE205836T1/de not_active IP Right Cessation
- 1997-06-03 EP EP97925987A patent/EP0853616B1/en not_active Expired - Lifetime
- 1997-06-03 HU HU9902026A patent/HUP9902026A3/hu unknown
- 1997-06-03 EA EA199800215A patent/EA199800215A1/ru unknown
- 1997-06-03 IL IL12312497A patent/IL123124A0/xx unknown
- 1997-06-03 PL PL97325122A patent/PL325122A1/xx unknown
- 1997-06-03 CN CN97190942A patent/CN1198158A/zh active Pending
- 1997-06-03 ES ES97925987T patent/ES2165061T3/es not_active Expired - Lifetime
- 1997-06-03 US US09/000,238 patent/US6057326A/en not_active Expired - Fee Related
- 1997-06-03 BR BR9702328A patent/BR9702328A/pt not_active Application Discontinuation
- 1997-06-03 AU AU30941/97A patent/AU3094197A/en not_active Abandoned
- 1997-06-03 DE DE69706823T patent/DE69706823T2/de not_active Expired - Fee Related
- 1997-06-03 KR KR1019980701225A patent/KR19990043993A/ko not_active Withdrawn
- 1997-06-03 CA CA002228492A patent/CA2228492C/en not_active Expired - Fee Related
- 1997-06-03 WO PCT/EP1997/002965 patent/WO1997049689A1/en not_active Ceased
- 1997-06-18 ZA ZA9705380A patent/ZA975380B/xx unknown
- 1997-06-20 AR ARP970102715A patent/AR008614A1/es unknown
-
1998
- 1998-02-20 NO NO980718A patent/NO980718L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0853616A1 (en) | 1998-07-22 |
| ES2165061T3 (es) | 2002-03-01 |
| ATE205836T1 (de) | 2001-10-15 |
| DE69706823T2 (de) | 2002-04-11 |
| MX9801408A (es) | 1998-05-31 |
| EA199800215A1 (ru) | 1998-08-27 |
| HUP9902026A3 (en) | 2000-07-28 |
| GB9613021D0 (en) | 1996-08-28 |
| IL123124A0 (en) | 1998-09-24 |
| KR19990043993A (ko) | 1999-06-25 |
| US6057326A (en) | 2000-05-02 |
| JPH11511761A (ja) | 1999-10-12 |
| NO980718L (no) | 1998-04-08 |
| ZA975380B (en) | 1998-01-05 |
| CN1198158A (zh) | 1998-11-04 |
| HUP9902026A2 (hu) | 2000-04-28 |
| WO1997049689A1 (en) | 1997-12-31 |
| PL325122A1 (en) | 1998-07-06 |
| DE69706823D1 (en) | 2001-10-25 |
| EP0853616B1 (en) | 2001-09-19 |
| CA2228492A1 (en) | 1997-12-31 |
| BR9702328A (pt) | 1999-07-20 |
| AU3094197A (en) | 1998-01-14 |
| NO980718D0 (no) | 1998-02-20 |
| CA2228492C (en) | 2007-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR008614A1 (es) | UN PROCEDIMIENTO PARA LA FABRICACIoN DE UNA COMPOSICION FARMACEUTICA QUE CONTIENE UN COMPUESTO DE PIRIMIDINA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DELMISMO, QUE TIENE ACTIVIDAD INHIBITORIA DE LA TIROSINA QUINASA, COMPUESTOS DE PIRIMIDINA, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y UN PROCEDIMI | |
| AR004320A1 (es) | Nuevos compuestos de pirimidina condensados biciclicos; un procedimiento para su preparacion; composiciones farmaceuticas que los contienen y su usocomo agentes terapeuticos, en particular como inhibidores de la tirosina quinasa. | |
| FI960399A0 (fi) | Perhydroisoindolijohdannaisia P-aineen antagonisteina | |
| EA200400466A1 (ru) | Производные пиперазина с антагонистической активностью к рецептору ccr1 | |
| BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
| ES2078798T3 (es) | Derivados de quinazolina. | |
| NO20052805L (no) | Substituerte pyrrolo-pyrazolderivater som kinase-inhibitorer | |
| UA84878C2 (ru) | Производные 2-пиридона как ингибиторы нейтрофилов эластазы, фармацевтическая композиция на их основе, способ их получения | |
| AR013746A1 (es) | Sustitucion bioisosterica de catecol por indazol en compuesto terapeuticos activos | |
| NO986055D0 (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| NO980919L (no) | 8-azabicyklo(3.2.1)okt-2-ene derivater, og deres anvendelse til fremstilling av et legemiddel | |
| PE20070832A1 (es) | Derivados de piridazinona como inhibidores de la tirosina quinasa | |
| BRPI0408727A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto | |
| DE602004012758D1 (de) | Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung | |
| AU4483000A (en) | Inhibitors of c-jun n-terminal kinases (jnk) | |
| CO5271675A1 (es) | Derivados de decahidro-isoquinolinas, proceso para su preparacion, composicion y compuestos farmaceuticos que los contienen | |
| AR035935A1 (es) | El empleo de un antagonista del receptor de nk-1 y una composicion farmaceutica que lo comprende | |
| NO963706L (no) | Benzenkondenserte heterosykliske derivater og deres anvendelse | |
| AR041255A1 (es) | Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso. | |
| MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
| AR037459A1 (es) | Antagonistas vi del receptor ccr-3 | |
| NO973213L (no) | Nye 2-(1H)-quinolinforbindelser, fremgangsmåter ved fremstilling av slike samt farmasöytiske sammensetninger omfattende disse | |
| AR036735A1 (es) | Derivados de 5-metoxi-8-aril-[1,2,4]triazolo[1,5-a]piridina | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento |